[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-distress\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-distress":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100593642",false,"NCT07009093","Utility of a Mobile Application for Young Women With Breast Cancer","Inclusion Criteria:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent\n* Age ≥ 18 and ≤ 45 years at the time of consent\n* Female\n* Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)\n* Histological confirmation of any type and stage (0-IV) of breast cancer\n* Screening (baseline) NCCN Distress Thermometer score ≥ 4\n* Access to a mobile device for trial purposes and an active email address\n* Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.\n* As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n\\- None","FEMALE","18 Years","45 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.",[25,26],"Breast Cancer","Cancer Distress",[28,25,29],"Cancer-related Distress","Young Adult Cancer","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":19},"2026-08",{"date":38,"type":19},"2030-01",{"name":40,"class":41},"Wake Forest University Health Sciences","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":49,"minAge":15,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100462509","NCT05302583","Aromatherapy Inhaler Use for HSCT Distress","Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress","Inclusion Criteria:\n\n* Autologous and Allogeneic patients admitted to E1 for planned HSCT\n* Patients with hematologic malignancies requiring HSCT\n* No allergies to lavender or peppermint essential oils\n* Must have received chemotherapy during preparative regimen (single or multi-agent regimen)\n* Adult patient over 18 years of age\n* Able to speak, read, and comprehend English\n* Willing and capable of providing informed consent\n\nExclusion Criteria:\n\n* Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion\n* Patients receiving a transplant for a germ cell tumor diagnosis\n* Unexpected\u002Funplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)\n* Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4\n* History of scleroderma\n* History of atrial fibrillation\n* Known history of G6PD deficiency\n* Allergic to lavender or peppermint essential oils\n* Pediatric patient 18 years of age or less\n* Unable to speak, read, and comprehend English\n* Unwilling or incapable of providing informed consent","ALL",{"count":51,"type":19},50,[22],"This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.",[26,55,56,57],"Cancer Coping","Hematopoetic Stem Cell Transplant","Aromatherapy","2026-05-29",{"date":60,"type":34},"2026-06-02",{"date":62,"type":34},"2025-06-16",{"date":64,"type":19},"2026-06",{"name":66,"class":41},"Stanford University",""]